Mabion (MAB)
- Share price (7-session average)
- 9.59 PLN-12.06% w/w
- Market cap
- PLN 133.2M
- 52-week range
- 6.70 – 11.22 PLN
Prices as of November 20, 2026, delayed.
Last updated: Source: ESEF / ESPI / GPW
Price Chart
About Mabion
Mabion is a biotechnology company providing contract services in biological drug development and manufacturing. The company has production and research facilities near Łódź.
This description was generated with the help of AI and may contain inaccuracies. Please verify important information from official sources.
Company Details
Data sourced from GPW and OpenFIGI. Updated periodically — verify with official sources.
News
Inwestorzy uwierzyli w Mabion. Kurs nadal rośnie
Parkiet
Rozszerzenie współpracy z WPD Pharmaceuticals S.A. – list intencyjny dotyczący wspólnej realizacji programu rozwoju biologicznych produktów leczniczych opartych na terapii celowanej w obszarze onkologii
ContractParkiet
Mabion dłużej poczeka na zysk
Parkiet
Mabion robi krok do przodu
Parkiet
Osiągnięcie pierwszego kamienia milowego na drodze do wprowadzenia MabionCD20 jako leku sierocego stosowanego w leczeniu immunologicznej trombocytopenii (ITP) – potwierdzenie zgłoszenia o wyznaczenie terminu spotkania z amerykańską Agencją ds. Żywności i Leków (FDA)
FilingParkiet
Zawarcie umowy sprzedaży niewykorzystywanych linii technologicznych
ContractParkiet
Communities
Frequently asked questions
- How much does a Mabion share cost?
- The 7-day average share price of Mabion (MAB) on GPW is 9.59 PLN.
- On which exchange is Mabion listed?
- Mabion is listed on GPW under the ticker MAB, ISIN: PLMBION00016.
- Is Mabion stock being shorted?
- Per the KNF short-selling register (as of November 22, 2026), there are no disclosed net short positions in Mabion. KNF discloses positions from 0.5% of share capital, so smaller ones are not visible.
Similar companies — Pharmaceuticals
Explore the market
This information is provided for informational purposes only and does not constitute investment advice or a recommendation. Listings describe companies by the stated criteria and are not an inducement to buy or sell any financial instrument. Verify figures against official sources before making any investment decision.